Company intelligence / Profile preview

Sephoris Pharmaceuticals

Jamul, California, United Statessephorispharma.com ↗

Ownership: Private
Development stage: Other

Overview

SP-160412 underwent a Phase II multicenter, double-blinded clinical trial for temporary relief of mild to moderate sunburn pain but the study was terminated and the program is discontinued. There are no reported positive or ongoing clinical results as of January 2025.

Therapeutic areas: NeurologyDermatology
Modalities: Small moleculeCombination drug
Industry: Biotech

Beyond the preview

Go deeper on Sephoris Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sephoris Pharmaceuticals.

Explore the full profile